

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Larry R. ROHRSCHEIDER

Serial No.: 10/593,202

Filed: September 15, 2006

For: METHODS AND COMPOSITIONS  
INVOLVING S-SHIP PROMOTER  
REGIONS

Group Art Unit: 3662

Examiner: Unknown


Atty. Dkt. No.: FHCC:016US

Confirmation No.: 5927

**CERTIFICATE OF ELECTRONIC TRANSMISSION**

I hereby certify that this correspondence is being  
electronically filed with the United States Patent and  
Trademark Office via EFS-Web on the date below:

March 20, 2007  
Date

  
Charles P. Landrum

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to

be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/FHCC:016US.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Charles P. Landrum  
Reg. No. 46,855  
Agent for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: March 20, 2007

Form PTO-1449 (modified)		Atty. Docket No.: <b>FHCC:016US</b>	Serial No.: <b>10/593,202</b>
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: <b>Larry R. ROHRSCHEIDER</b>	
		Filing Date: <b>September 15, 2006</b>	Group: <b>3662</b>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,580,859	12/3/96	Felgner et al.	514	44	3/18/94
	A2	5,589,466	12/31/96	Felgner et al.	514	44	1/26/95
	A3	5,616,491	4/1/97	Mak et al.	435	354	9/14/95
	A4	5,656,610	8/12/97	Shuler et al.	514	44	6/21/94
	A5	5,702,932	12/30/97	Hoy et al.	435	172.3	6/7/95
	A6	5,736,524	4/7/98	Content et al.	514	44	11/14/94
	A7	5,780,448	7/14/98	Davis	514	44	11/4/96
	A8	5,945,100	8/31/99	Fick	424	932.1	7/31/96
	A9	5,981,274	11/9/99	Tyrrell et al.	435	320.1	9/18/96
	A10	5,994,624	11/30/99	Trolinder et al.	800	278	10/20/97

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Butler and Kadonaga, "The RNA polymerase II core promoter: a key component in the regulation of gene expression," <i>Genes Dev.</i> , 16:2583-2592, 2002.
	C2	Charge and Rudnicki, "Fusion with the Fused: A New Role for Interleukin-4 in the Building of Muscle," <i>Cell</i> , 113:422-423, 2003.
	C3	Dailey <i>et al.</i> , "Interaction between a Novel F9-Specific Factor and Octamer-Binding Proteins Is Required for Cell-Type-Restricted Activity of the Fibroblast Growth Factor 4 Enhancer," <i>Mol. Cell. Biol.</i> , 14:7758-7769, 1994.

25752989.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: FHCC:016US	Serial No.: 10/593,202
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Larry R. ROHRSCHEIDER	
		Filing Date: September 15, 2006	Group: 3662
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C4	Dor <i>et al.</i> , "Adult pancreatic $\beta$ -cells are formed by self-duplication rather than stem-cell differentiation," <i>Nature</i> , 429:41-46, 2004.
	C5	Grompe and Finegold, "Liver Stem Cells," In: <i>Stem Cell Biology</i> , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001.
	C6	Gupta <i>et al.</i> , "The SH2 Domain-containing Inositol 5'-Phosphatase (SHIP) Recruits the p85 Subunit of Phosphoinositide 3-Kinase during Fc $\gamma$ RIIb1-mediated Inhibition of B Cell Receptor Signaling," <i>J. Biol. Chem.</i> , 274:7489-7494, 1999.
	C7	Horn <i>et al.</i> , "The inositol 5-phosphatase SHIP is expressed as 145 and 135 kDa proteins in blood and bone marrow cells <i>in vivo</i> , whereas carboxyl-truncated forms of SHIP are generated by proteolytic cleavage <i>in vitro</i> ," <i>Leukemia</i> , 15:112-120, 2001.
	C8	Kavanaugh <i>et al.</i> , "Multiple forms of an inositol polyphosphate 5-phosphatase form signaling complexes with Shc and Grb2," <i>Current Biol.</i> , 6:438-445, 1996.
	C9	Lioubin <i>et al.</i> , "p150 <sup>Ship</sup> , a signal transduction molecule with inositol polyphosphate-5-phosphatase activity," <i>Genes Devel.</i> , 10:1084-1095, 1996.
	C10	Lioubin <i>et al.</i> , "Shc, Grb2, Sos1, and a 150-Kilodalton Tyrosine-Phosphorylated Protein Form Complexes with Fms in Hematopoietic Cells," <i>Mol. Cell Biol.</i> , 14(9):5682-5691, 1994.
	C11	Liu <i>et al.</i> , "The SH2-Containing Inositol Polyphosphate 5-Phosphatase, Ship, Is Expressed During Hematopoiesis and Spermatogenesis," <i>Blood</i> , 91:2753-2759, 1998.
	C12	Lucas and Rohrschneider, "A Novel Spliced Form of SH2-Containing Inositol Phosphatase Is Expressed During Myeloid Development," <i>Blood</i> , 93:1922-1933, 1999.
	C13	NCBI accession #AF235499
	C14	Pesce <i>et al.</i> , "In line with our ancestors: <i>Oct-4</i> and the mammalian <i>germ</i> ," <i>BioEssays</i> , 20:722-732, 1998.
	C15	Rohrschneider <i>et al.</i> , "Structure, function, and biology of SHIP proteins," <i>Genes Devel.</i> , 14:505-520, 2000.
	C16	Rohrschneider, "SHIP Inositol Phosphate Phosphatases," In: <i>Handbook of Cell Signaling</i> , Bradshaw and Dennis (Eds.), 148(2):147-151, Elsevier Sciences (USA), 2003.
	C17	Rohrschneider, "The intron 5/6 promoter region of the <i>ship1</i> gene regulates expression in stem/progenitor cells of the mouse embryo," <i>Developmental Biology</i> , 283:503-521, 2005.

25752989.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: <b>FHCC:016US</b>	Serial No.: <b>10/593,202</b>
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: <b>Larry R. ROHRSCHEIDER</b>	
		Filing Date: <b>September 15, 2006</b>	Group: <b>3662</b>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C18	Sly <i>et al.</i> , "SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide," <i>Experimental Hematology</i> , 31(12):1170-1181, 2003.
	C19	Tu <i>et al.</i> , "Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein," <i>Blood</i> , 98:2028-2038, 2001.
	C20	Wolf <i>et al.</i> , "Cloning of the Genomic Locus of Mouse SH2 Containing Inositol 5-Phosphatase (SHIP) and a Novel 110-kDa Splice Isoform, SHIP $\delta$ ," <i>Genomics</i> , 69(1):104-112, 2000.

25752989.1

EXAMINER: /Michael Wilson/

DATE CONSIDERED: 05/20/2009

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.W./